Latigo Biotherapeutics, Inc. (LTGO)
| Market Cap | 978.58M |
| Revenue (ttm) | n/a |
| Net Income | -111.14M |
| EPS | -116.74 |
| Shares Out | 66.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 242,898 |
| Open | 14.09 |
| Previous Close | 14.00 |
| Day's Range | 13.50 - 14.90 |
| 52-Week Range | 13.50 - 25.93 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 52.25 (+254.0%) |
| Est. Earnings | Nov 19, 2026 |
About LTGO
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly k... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for LTGO stock is "Strong Buy." The 12-month stock price target is $52.25, which is an increase of 254.00% from the latest price.
News
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Completed upsized initial public offering, including full exercise of the underwriters' option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expe...
Latigo Biotherapeutics Earnings release: Q2 2026
Latigo Biotherapeutics released its Q2 2026 earnings on September 3, 2026, summarizing the period's financial results.
Latigo Biotherapeutics Quarterly report: Q2 2026
Latigo Biotherapeutics has published its Q2 2026 quarterly earnings report on September 3, 2026.
Latigo Biotherapeutics Slides: Corporate presentation
Latigo Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 3, 2026.
Latigo Biotherapeutics initiated with a Buy at Jefferies
Jefferies initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $50 price target The firm believes LTG-001 will show at least as good efficacy as Suzetrigine in its…
Latigo Biotherapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Latigo Biotherapeutics (LTGO) with an Outperform rating and $36 price target
Latigo Biotherapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $50 price target implying 127% upside. The company has two “binary catalysts and second-mover ...
Latigo Biotherapeutics initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $73 price target Latigo is clinical-stage biotechnology company developing non-opioid pain medicines without add...
Latigo Biotherapeutics opens at $21, IPO priced at $18 per share
Latigo Biotherapeutics (LTGO) – a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines – priced 19.2M shares at $18.00. The deal size was increased to ...
Latigo Biotherapeutics indicated to open at $20, IPO priced at $18
Latigo Biotherapeutics (LTGO) priced 19.2M shares at $18.00. The deal size was increased to 19.2M shares of common stock from 16M shares of common stock and priced at the high-end…
Latigo Biotherapeutics 19.2M share IPO priced at $18.00
The deal size was increased to 19.2M shares of common stock from 16M shares of common stock and priced at the high-end of the $16.00-$18.00 range. Goldman Sachs, Jefferies, Leerink…
Latigo Biotherapeutics Registration statement: Registration filing
Latigo Biotherapeutics filed a registration statement on August 4, 2026, providing details about a securities offering with the SEC.
Latigo Biotherapeutics 16M share IPO price range $16.00-$18.00
Goldman Sachs, Jefferies, Leerink and Guggenheim are acting as joint book running managers for the offering.
Latigo, BlossomHill launch US IPOs as biotech listings rebound
Drug developers Latigo Biotherapeutics and BlossomHill Therapeutics launched their U.S. initial public offerings on Monday riding the wave of biotech listings.
Latigo Biotherapeutics Registration statement: Registration filing
Latigo Biotherapeutics filed a registration statement on August 3, 2026, providing details about a securities offering with the SEC.
Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines, today announced the publicati...
Acute and chronic pain relief biotech Latigo Biotherapeutics files for a $100 million IPO
Latigo Biotherapeutics, a Phase 3-ready biotech developing non-opioid, oral therapies for acute and chronic pain, filed on Friday with the SEC to raise up to $100 million in an initial public offering...
Latigo Biotherapeutics IPO Registration Document (S-1)
Latigo Biotherapeutics has filed to go public with an IPO on the NASDAQ